← Leaderboards
James Andrews
University Of Washington
$2,069,622
Attributed
$2,241,250
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $803.7K · FY2018–25$1M$750K$500K$250K$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,241,250 · 3
By mechanism
K23$1,586,993 · 1
R21$343,257 · 1
R03$311,000 · 1
Top collaborators
- Eleni Tiniakou2 shared
Most similar at University Of Washington
Same institution · by research overlap
- Connie L Celum$55,222,861
- Peter J Leary$6,420,826
- Anna Wald$34,443,936
- Abhijit Prakash Limaye$10,475,049
- Stephanie T Page$4,517,736
Others in their field
Other Emerging Leaders on “Muscle Strength”
- James Dale Berry · Brigham And Women'S Hospital$6,045,501
- Harshini Neelakantan · Ridgeline Therapeutics, Llc$5,955,890
- Ian R Lanza · Mayo Clinic Rochester$3,282,415
- Anthony D Saleh · Mirecule, Inc.$3,123,687
- Carolyn Glass · Duke University$3,115,222
- Andrew Donald Ray · Roswell Park Cancer Institute Corp$3,008,512
Research focus
Muscle StrengthPhysically HandicappedFunctional OutcomesHospitalsAcuteDual-Energy X-Ray AbsorptiometryMuscle FormActivities Of Daily LivingRisk FactorsSarcopeniaSepsisHospitalizationDisabilityElderlyFutureHand StrengthCohortPathogenesisSkeletal MuscleAdultAlzheimer&AposAgingMuscleFunding
Grant awards (13)
The MIGHT Trial - An Exploratory Clinical Trial of IVIG in anti-HMGCR ImmuneMediated Necrotizing Myopathy$114,039
R21 · FY2025 · AR · contact PI
The MIGHT Trial - An Exploratory Clinical Trial of IVIG in anti-HMGCR ImmuneMediated Necrotizing Myopathy$229,218
R21 · FY2024 · AR · contact PI
Sarcopenia as a Predictor of Cognitive Impairment in Older Adults Hospitalized for COVID-19$187,920
K23 · FY2022 · AG · contact PI
Sarcopenia as a Predictor of Hospital-Associated Disability in Older Adults$116,110
K23 · FY2022 · AG · contact PI
Sarcopenia as a Predictor of Hospital-Associated Disability in Older Adults$69,940
K23 · FY2022 · AG · contact PI
Sarcopenia as a Predictor of Hospital-Associated Disability in Older Adults$188,892
K23 · FY2021 · AG · contact PI
Sarcopenia as a Predictor of Hospital-Associated Disability in Older Adults$261,105
K23 · FY2020 · AG · contact PI
Sarcopenia as a Predictor of Hospital-Associated Disability in Older Adults$198,244
K23 · FY2020 · AG · contact PI
Sarcopenia as a Predictor of Hospital-Associated Disability in Older Adults$188,892
K23 · FY2020 · AG · contact PI
Sarcopenia as a Predictor of Functional Outcomes of Acute Illness in Older Adults with Dementia$155,500
R03 · FY2020 · AG · contact PI
Sarcopenia as a Predictor of Hospital-Associated Disability in Older Adults$188,113
K23 · FY2019 · AG · contact PI
Sarcopenia as a Predictor of Functional Outcomes of Acute Illness in Older Adults with Dementia$155,500
R03 · FY2019 · AG · contact PI
Sarcopenia as a Predictor of Hospital-Associated Disability in Older Adults$187,777
K23 · FY2018 · AG · contact PI